Hepatitis C Medicines Financially Inaccessible In Many Nations, WHO Study Shows

STAT: Hepatitis C drugs remain unaffordable in many countries, says WHO study
“In the latest effort to quantify the burden of expensive medicines, a new study found that the cost of two widely used hepatitis C treatments remains out of reach for people in many poor countries and poses a ‘financial and ethical dilemma’ for payers and doctors. In general, current prices are unaffordable and, as a result, poorer countries may be paying higher prices than wealthier nations, according to the study, which appeared on Tuesday in PLOS Medicine and was conducted by World Health Organization officials…” (Silverman, 5/31).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.